Tofacitinib combined with melanocyte protector α-MSH to treat vitiligo through dextran based hydrogel microneedles.
Carbohydr Polym
; 305: 120549, 2023 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-36737198
ABSTRACT
Vitiligo can cause serious damage to the appearance of patients and affect physical and mental health, but there is currently no simple and effective treatment. According to the theory of autoimmune disorder, the separable hydrogel microneedles delivering alpha-melanocyte-stimulating hormone (α-MSH) and tofacitinib were designed to treat vitiligo. This hydrogel microneedles were formed by dextran methacrylate (DexMA) and cyclodextrin-adamantane based host-guest supramolecules (HGSM) through CC double bond polymerization and host-guest assembly. The microneedle tips formed by the double cross-linked hydrogel can pierce the stratum corneum and deliver melanocyte protector α-MSH and JAK inhibitor tofacitinib directly to the epidermis and dermis. Under the treatment of α-MSH/tofacitinib microneedles, massive deposition of melanin in epidermis and hair follicles significantly accelerated skin and hair pigmentation.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vitiligo
/
Alfa-MSH
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article